Julie Derving Karsbøl

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 648 citations · Full text

Diabetes Management, Sustain 1, Diabetes +7

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Bo Åhrén, Luís Masmiquel, Harish Kumar et al. · The Lancet Diabetes & Endocrinology · 2017 · 445 citations

Diabetes Management, Cardiovascular Disease, Medicine +9

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

Lene Jensen, Hans Helleberg, Ad F. Roffel et al. · European Journal of Pharmaceutical Sciences · 2017 · 161 citations · Full text

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

Thomas Marbury, Anne Flint, Jacob Jacobsen et al. · Clinical Pharmacokinetics · 2017 · 115 citations · Full text

No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial

László Hegedüs, Steven I. Sherman, R. Michael Tuttle et al. · Diabetes Care · 2017 · 60 citations